Overcoming Bioavailability 'Roadblocks' with LBDDS

Abstract

Industry is witnessing opportunities in novel drug discovery for the formulation of new NCEs in lipidbased drug delivery systems (LBDDS) so that bioavailability is improved." "Drug release is the important determinant to ensure maximum bioavailability at the site of action. [...]lipid formulations could be tailored to achieve desired drug-release kinetics by careful selection of lipid excipients." There may be issues as ratios of lipid components change from batch-tobatch. Because of these variables, it is recommended that drug developers work with experts who have extensive experience and knowledge of the development of LBDDS." [...]while the excipients used to construct lipid formulations are usually quite inert, many of these contain impurities, such as peroxides, aldehydes, or formic acid, that may trigger degradation pathways that are not seen when the same API is formulated in a solid formulation," specifies Speybroeck.